Donor Lymphocyte Infusion Post Transplant
Phase I/II Study Using Prophylactic Donor Lymphocyte Infusion Early Post-Transplant After Allogeneic Hematopoietic Cell Transplantation Using Post-Transplantation Cyclophosphamide for High-Risk Hematologic Malignancies
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1/2
- Enrollment
- 430 patients (estimated)
- Sponsors
- National Cancer Institute (NCI)
- Tags
- Donor Lymphocyte Infusion (DLI), Post-Allogeneic Stem Cell Transplant
- Trial Type
- Treatment
- Last Update
- 2 weeks ago
- SparkCures ID
- 2065
- NCT Identifier
- NCT05327023
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.